Cargando…

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

Venetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated the safety and efficacy of Ven and dexamethasone (VenDex) combination in patients with t(11;14) positive relapsed/refractory (R/R) multiple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaufman, Jonathan L., Gasparetto, Cristina, Schjesvold, Fredrik H., Moreau, Philippe, Touzeau, Cyrille, Facon, Thierry, Boise, Lawrence H., Jiang, Yanwen, Yang, Xiaoqing, Dunbar, Fengjiao, Vishwamitra, Deeksha, Unger, Stefanie, Macartney, Tammy, Pesko, John, Yu, Yao, Salem, Ahmed Hamed, Ross, Jeremy A., Hong, Wan‐Jen, Maciag, Paulo C., Pauff, James M., Kumar, Shaji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986778/ https://www.ncbi.nlm.nih.gov/pubmed/33368455 http://dx.doi.org/10.1002/ajh.26083

Ejemplares similares

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report
por: Yang, Yang, et al.
Publicado: (2021)

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
por: Todoerti, Katia, et al.
Publicado: (2021)

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation
por: Sundaramoorthy, Pasupathi, et al.
Publicado: (2018)

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
por: Popovic, Relja, et al.
Publicado: (2021)

Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review
por: Valliani, Salimah, et al.
Publicado: (2020)

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015)

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
por: Abuelgasim, Khadega A., et al.
Publicado: (2020)

Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma
por: Dalland, Joanna C., et al.
Publicado: (2021)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
por: Bal, Susan, et al.
Publicado: (2023)

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
por: Offner, Fritz, et al.
Publicado: (2023)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Venetoclax ex vivo functional profiling predicts improved progression-free survival
por: Gupta, Vikas A., et al.
Publicado: (2022)

1114 Fetal demise during the COVID-19 pandemic: are rates increasing?
por: Ozimek, John A., et al.
Publicado: (2021)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

Back pain in elite sports: A cross-sectional study on 1114 athletes
por: Fett, Daniela, et al.
Publicado: (2017)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence
por: Kitadate, Akihiro, et al.
Publicado: (2021)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)
por: Bahlis, Nizar J., et al.
Publicado: (2023)

1114. Identifying and Addressing Knowledge Gaps in Influenza Management with Targeted Continuing Medical Education
por: Robinson, Katie, et al.
Publicado: (2020)

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report
por: Nassereldine, Hasan, et al.
Publicado: (2022)

Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma
por: Wang, Jinghua, et al.
Publicado: (2022)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification
por: Nakahara, Wataru, et al.
Publicado: (2023)

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
por: Gupta, Vikas A, et al.
Publicado: (2021)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

Draft Genome Sequence of the White-Rot Fungus Schizophyllum Commune IUM1114-SS01
por: Kim, Da-Woon, et al.
Publicado: (2020)

T cell acute lymphoblastic leukemia with t(11;14)(p13;q11) and trisomy 8
por: Safavi, Moeinadin, et al.
Publicado: (2021)

Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma
por: Wang, Yazhu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lkq5bqamgvl289rc49m4m91si2